Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0628

View: 1063 Download: 105 Crossref: 2

Correspondence

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(4):1005-1008. Published online May 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0394

View: 1669 Download: 64

Original Article

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 3186 Download: 319 Web of Science: 8 Crossref: 2

Editorial

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Naoshi Nishida

Clin Mol Hepatol. 2024;30(4):682-688. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0324

View: 1940 Download: 102 Crossref: 1

Original Article

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 4857 Download: 431 Web of Science: 11 Crossref: 9

Letter to the Editor

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura, The Kurume Liver Cancer Study Group of Japan

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

View: 4304 Download: 216 Web of Science: 7 Crossref: 8

1 |

Viewed By 7410	MAFLD: How is it different from NAFLD?
Viewed By 6995	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5604	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5360	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4788	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 270	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search